|
| revenue = US $445-$500 million | revenue_year = 2014 | operating_income = US $42.8 million | income_year = 2014 | net_income = US $53-$55 million | net_income_year = 2014 | module = | website = | footnotes = 〔(【引用サイトリンク】title=Emergent BioSolutions Corporate Governance )〕〔(【引用サイトリンク】url=http://finance.yahoo.com/q/ks?s=EBS+Key+Statistics )〕〔(【引用サイトリンク】url=http://finance.yahoo.com/q/is?s=EBS&annual )〕〔(【引用サイトリンク】url=http://finance.yahoo.com/q/bs?s=EBS+Balance+Sheet&annual )〕 | intl = yes }} Emergent BioSolutions is a multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland.〔(【引用サイトリンク】url=http://emergentbiosolutions.com/node/57 )〕 It develops vaccines and antibody therapeutics for infectious diseases, oncology and autoimmune disorders, and provides medical devices for biodefense purposes. Among the company’s notable products is BioThrax (Anthrax Vaccine Adsorbed), the only anthrax vaccine licensed by the U.S. Food and Drug Administration (FDA). The company also manufactures pharmaceuticals for adults and children with acute blood disorders, people undergoing certain liver transplants, palliative care for chemo or radiation therapy patients, hemophilia B and a ''varicella'' (Chickenpox) vaccine for high risk patients. The company has two divisions: a Biodefense division for medical countermeasures and a Biosciences division to treat infectious disease, autoimmune diseases, and cancer. Fuad El-Hibri, the founder of the company and former CEO, led the company since its founding as BioPort Inc.〔 until his retirement on April 1, 2012. He continues to serve as the executive chairman of Emergent BioSolutions’ board of directors. The current CEO is Daniel Abdun-Nabi. == Anthrax vaccine == 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Emergent BioSolutions」の詳細全文を読む スポンサード リンク
|